ERBB2 and gastric cancer: The findings demonstrated that GC patients with various clinical-pathological characteristics, including males and females, those undergoing surgery or 5-FU-based adjuvant therapy, and those who were HER2-negative or HER2-positive, had a worse prognosis when high PVT1 expression was present (Table 1, p < 0.05).